SULFATRIM

This brand name is authorized in Nigeria. It is also authorized in Canada, Tunisia, United States.

Active ingredients

The drug SULFATRIM contains a combination of these active pharmaceutical ingredients (APIs):

1	Sulfamethoxazole UNII JE42381TNV - SULFAMETHOXAZOLE
	Sulfamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis.
	Read more about Sulfamethoxazole
2	Trimethoprim UNII AN164J8Y0X - TRIMETHOPRIM
	Trimethoprim is a dihydrofolate reductase inhibitor, inhibiting the conversion of bacterial dihydrofolic acid to tetrahydrofolic acid, required for the synthesis of some amino acids. Its effects are considerably greater on the cells of micro-organisms than on the mammalian cells.
	Read more about Trimethoprim

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A11-100616	Tablet	SULFATRIM TABLETS TAB 400 mg; 80 mg 100 X 10Tablets	135 NF-PP-341937 SULFATRIM TABLETS Co-Trimoxazole Tablets Sulfamethoxazole BP 400mg, Trimethoprim BP 80mg (EXCIPIENTS: Magnesium Stearate BP, Methyl Hydroxybenzoate BP, Propyl Hydroxybenzoate BP, Sodium Lauryl Sulfate BP, Sodium Starch Glycolate BP, Maize Starch BP, Purified Talc BP) A11-100616 Drugs Nigerian Products 100x10tablets POM 1 7/10/2023 SHALINA HEALTHCARE NIGERIA LIMITED, 19 Fatai Atere Way, Matori, Mushin 18183973 theophilus.adimoha@shalina.com shalina healthcare Nigeria Limited , Block 3B, Westerner Industrial Avenue, off Lagos-Ibadan Expressway, Isheri, Ifo Local Government Area, Ogun State, Nigeria , Nigeria	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01EE01	Sulfamethoxazole and trimethoprim	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01E Sulfonamides and trimethoprim → J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives
Discover more medicines within J01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	00445266, 00445274, 00445282
NG	Registered Drug Product Database	A11-100616
TN	Direction de la Pharmacie et du Médicament	9223021, 9223022
US	FDA, National Drug Code	0121-0854, 67296-1163, 68788-7345